Industry perspectives on biomarker qualification

Biomarkers have the potential to expedite drug development, increase patient safety, and optimize clinical response. Yet few have achieved regulatory qualification. A survey was conducted to clarify industry's perspective on biomarker qualification and identify the most promising biomarkers for drug development. The results across toxicities/clinical areas highlight challenges in regulatory qualification, although early prioritization and alignment on an evidentiary standard framework are key factors in facilitating biomarker development and qualification.

[1]  G. Mills,et al.  Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward , 2006, Clinical Cancer Research.

[2]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[3]  Whole Grain Label Statements.  Guidance for Industry and FDA Staff , 2006 .

[4]  R. Kerbel,et al.  Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development , 2004, Clinical Cancer Research.

[5]  C. Lathia.  Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development? , 2002, Disease markers.

[6]  Frank D Sistare,et al.  Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification. , 2011, Biomarkers in medicine.

[7]  F. Dieterle,et al.  Promises of Biomarkers in Drug Development – A Reality Check , 2007, Chemical biology & drug design.

[8]  R. Bellomo,et al.  Biomarkers of acute kidney injury in anesthesia, intensive care and major surgery: from the bench to clinical research to clinical practice. , 2010, Minerva anestesiologica.

[9]  D. Javitt,et al.  Neurophysiological biomarkers for drug development in schizophrenia , 2008, Nature Reviews Drug Discovery.

[10]  J. Growdon.  Incorporating biomarkers into clinical drug trials in Alzheimer's disease. , 2001, Journal of Alzheimer's disease : JAD.

[11]  D Amakye,et al.  A Prototypical Process for Creating Evidentiary Standards for Biomarkers and Diagnostics , 2008, Clinical pharmacology and therapeutics.

[12]  John A. Wagner,et al.  Overview of Biomarkers and Surrogate Endpoints in Drug Development , 2002, Disease markers.

[13]  Mark R. Trusheim,et al.  Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.

[14]  Jiri Aubrecht,et al.  The current status of biomarkers for predicting toxicity , 2013, Expert opinion on drug metabolism & toxicology.

[15]  Martina Musteen,et al.  "Alertness to International Business Opportunities: Firm Characteristics, Experience & Networks" , 2014 .

[16]  H. Watkins,et al.  Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. , 2011, Circulation research.

[17]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[18]  S. Amur,et al.  Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization , 2015, Clinical pharmacology and therapeutics.

[19]  Malcolm Rowland,et al.  Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2004, Pharmaceutical Research.

[20]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[21]  Joel Lexchin,et al.  The cost of drug development: a systematic review. , 2011, Health policy.

[22]  R. Frank,et al.  New estimates of drug development costs. , 2003, Journal of health economics.

[23]  Ara Darzi,et al.  Preparing for precision medicine. , 2012, The New England journal of medicine.

[24]  C. Altar.  The Biomarkers Consortium: On the Critical Path of Drug Discovery , 2008, Clinical pharmacology and therapeutics.

[25]  A. Clark,et al.  Genome-based biomarkers for adverse drug effects, patient enrichment and prediction of drug response, and their incorporation into clinical trial design. , 2006, Personalized medicine.

[26]  F. Frueh,et al.  Biomarker qualification pilot process at the US Food and Drug Administration , 2007, The AAPS Journal.

[27]  James L Stevens,et al.  The future of drug safety testing: expanding the view and narrowing the focus. , 2009, Drug discovery today.

[28]  Frank Dieterle,et al.  Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring , 2009, Expert opinion on drug metabolism & toxicology.

[29]  R. Hargreaves,et al.  Clinical biomarkers in drug discovery and development , 2003, Nature Reviews Drug Discovery.